(NASDAQ: THAR) Profile
OUR NEW PROFILE IS: (NASDAQ: THAR) _________________ WHEN WE LOOKED AT THIS ONE BACK IN FEB IT RAN OVER 100% IN JUST 6 SESSIONS THAR HAS A FLOAT OF JUST UNDER 12 MILLION RIGHT NOW READ THE INVESTOR PRESENTATION HERE ___________________ Hello Everyone, We have another profile for you to watch pull […]
(Nasdaq: NCPL) Profile
REVENUE GROWTH OF 55% YEAR-OVER-YEAR TO $8.5 MILLION AS COMPARED TO $5.5 MILLION IN FISCAL 2022 FIRST QUARTER OF FISCAL YEAR 2023 SHOWED REVENUE GROWTH OF 13% YEAR-OVER-YEAR TO $1.5 MILLION, COMPARED TO REVENUE OF $1.3 MILLION IN THE PREVIOUS YEAR THE COMPANY BOASTS MORE THAN 100,000 USERS ALREADY WITH OVER $5O MILLION RAISED SO FAR THIS […]
(Nasdaq: TRNR) Profile
OUR NEW PROFILE IS: (NASDAQ: TRNR) ___________________________________ IN MAY, FORME ANNOUNCED A PARTNERSHIP WITH AETHOS, A HOTEL BRAND WITH LOCATIONS IN PORTUGAL, SPAIN AND ITALY THAT WILL PUT FORME’S CONNECTED FITNESS MIRRORS IN ALL OF ITS HOTELS AND MEMBER CLUBS. ANNUALIZED RECURRING REVENUE PER HOUSEHOLD IN Q1 2023 MORE THAN TRIPLES YOY TO $1,650 LAST MONTH, THE COMPANY ANNOUNCED A DISTRIBUTION PARTNERSHIP WITH THE […]
(Nasdaq: TLSA) Profile
OUR NEW PROFILE IS: (NASDAQ: TLSA) READ THE INVESTOR PRESENTATION HERE HELLO EVERYONE, We have a new profile for Monday’s session. This is another company that we have never looked at before on this newsletter before. Pull up TLSA right away. Historically, monoclonal antibodies, such as blockbuster drug, Humira®, have performed as the best selling drugs in […]
Nasdaq: ATAI Profile
OUR NEW PROFILE IS: (NASDAQ: ATAI) __________ CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $227.5 MILLION AS OF JUNE 30, 2023 ATAI OFFERS A DIVERSE PIPELINE OF DRUGS AND A FOCUS ON COMPOUNDS WITH PRIOR EVIDENCE IN HUMANS, UPCOMING INFLECTION POINTS (MULTIPLE PHASE 1 AND PHASE 2 PROOF-OF-CONCEPT TRIAL READOUTS ARE EXPECTED IN THE NEXT […]
(Nasdaq: NLSP) Profile
OUR NEW PROFILE IS: (NASDAQ: NLSP) NLSP HAS OVER 100 PATENTS IN 140 DIFFERENT COUNTRIES JASON MCCARTHY FROM MAXIM GROUP INITIATED A “BUY RATING” ON NLSP WITH A $4.00 PRICE TARGET BACK IN JAN NLSP HAS A LOW FLOAT WITH 14.8 MILLION SHARES COUPLED WITH A WELL FUNDED CASH POSITION OF $8.9MILLION (AS OF DEC. […]
(Nasdaq: OKYO) Profile
OUR NEW PROFILE IS: (NASDAQ: OKYO) OKYO IS SITTING WITH $4.0 MILLION CASH AS OF 31 MARCH 2023 OKYO ANTICIPATES HAVING TOPLINE DATA ON ITS DRUG, OK-101, IN QUARTER 4 OF 2023 _______________________________ Hello Everyone, We have another profile for you to research for Thursday’s session. So far this one has closed green 3 sessions in a row […]
(NYSE American: MAIA) Profile
OUR NEW PROFILE IS: (NYSE AMERICAN: MAIA) THE COMPANY HAD CASH TOTALING APPROXIMATELY $9.1 MILLION AS OF JUNE 30, 2023 MAIA BIOTECHNOLOGY ANNOUNCES SHARE REPURCHASE PROGRAM JUST LAST WEEK!! MAIA HAS CLOSED GREEN 4 SESSIONS IN A ROW AFTER BOUNCING OFF OF THE 52 WEEK LOW, TRIGGERING A MAJOR REVERSAL READ THE INVESTOR PRESENTATION […]
(Nasdaq: GWAV) Profile
OUR NEW PROFILE IS: (NASDAQ: GWAV) GWAV GENERATED $1.23MN IN POSITIVE CASH FLOWS FROM OPERATIONS DURING THE SIX MONTHS ENDING ON JUNE 30, 2023 GREENWAVE GENERATED OVER $18 MILLION IN REVENUE IN THE FIRST HALF OF THE YEAR GWAV OPERATES 13 METAL RECYCLING FACILITIES IN VIRGINIA, NORTH CAROLINA, AND CLEVELAND, OH YAHOO FINANCE HAS THE FLOAT AT JUST 8.59 […]
(Nasdaq: MYSZ) Profile
OUR NEW PROFILE IS: (NASDAQ: MYSZ) MYSZ REPORTED A STAGGERING 61% INCREASE IN CONSOLIDATED REVENUE, REACHING A TOTAL OF $1,290,000 FOR THE THREE MONTHS ENDED JUNE 30, 2023. THIS SURGE IN REVENUE IS CHIEFLY ATTRIBUTED TO THE GROWTH WITNESSED AT ORGAD AND THE STRATEGIC ACQUISITION OF NAIZ FIT DOWNLOAD THE INVESTOR PRESENTATION HERE ________________________________ HELLO EVERYONE, […]